Dienogest was synthesized in 1979 in Jena , Germany under the leadership of Prof. Kurt Ponsold, was initially referred to as STS-557 .   It was found that its potency was 10 times that of levonorgestrel .  The first product on the market to contain dienogest was a combined oral contraceptive pill (with ethinylestradiol), Valette, introduced in 1995 and made by Jenapharm .  In 2007, dienogest was introduced as Dinagest in Japan for the treatment of endometriosis, and it was subsequently marketed for this indication as Visanne in Europe and Australia in December 2009 and April 2010, respectively.  Qlaira was introduced in Europe in 2009 and Natazia was introduced in the United States in 2010. 
The DEXTRUS pacing lead is an extendable-retractable, active fixation lead designed to provide a larger electrically-active surface area for enhanced threshold performance. The lead features a familiar feel with durable and predictable helix extension-retraction performance and an inner coil designed for predictable torque response. The DEXTRUS lead is designed for an easy lead implant experience with mapping capability, a radiopaque helix and tip extension indicator and a flexible tip designed for flexible placement options within the right atrium and right ventricle.